Health Discovery, NeoGenomics Sign Cancer Testing License Pact | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostic technologies developer Health Discovery said today that it has licensed some of its biomarker-based testing tools for hematopoietic and solid tumor cancers to NeoGenomics for $1 million in cash, 1.4 million shares in NeoGenomics stock, milestone payments of up to $5 million, and ensuing royalties.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.